Skip to content

Study · Not a test of the peptide alone · 2011

1 result

Conformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor.

Grieco P, Brancaccio D, Novellino E, Hruby VJ, Carotenuto A

European journal of medicinal chemistry23 May 2011Cited by 14 (Europe PMC)

PMID21652123 (opens in a new tab)PMCIDPMC5102844 (opens in a new tab)DOI10.1016/j.ejmech.2011.05.038 (opens in a new tab)PepBankPUB-21652123
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cell-free)Other

    Solution NMR in different environments and docking within h-MC4R models gave conformations of MTII and SHU9119 that differ and can help explain their different activities.

    In plain wordsIn lab and computer studies, the shapes of MTII and SHU9119 differ, which may explain their different activities.

    Peptide
    Melanotan II
    Outcome
    Not applicableSolution conformation of MTII and docking at h-MC4R
    Study

    n: not reported in source

    solution NMR in water, water/DMSO and DPC micelles; docking on h-MC4R models
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The conformational preferences of the cyclic melanocortin ligands MTII (Ac-Nle(4)-c[Asp(5)-His(6)-DPhe(7)-Arg(8)-Trp(9)-Lys(10)]-NH(2))
    1 context sentence
    Summary · context
    NMR and docking studies revealed intriguing differences which can help explain the different activities of these two ligands.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.